Dexcom Receives FDA Approval for Continuous Glucose Monitor
Dexcom has announced it has received FDA approval of a new continuous glucose monitoring system, according to a news release.
The Dexcom G4 PLATINUM system consists of three parts: a sensor, transmitter and monitor. According to the company, features include a long transmission range, small profile, LCD display, customizable alerts with specific tones and a "hypo alert" setting at 55 mg/dl.
"Improved accuracy in the critical hypoglycemic range is most important from a life-saving point of view," said Terrance H. Gregg, Dexcom CEO, in the release. "The Dexcom G4 PLATINUM fulfills the promise of CGM for people with diabetes by providing accurate and reliable real-time performance."
Dexcom is headquartered in San Diego.
Related Articles on FDA Clearances:
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- How Physician Thinking Changes After Working in ACOs
- 2014 Financial Impact Analysis Doesn't Stop With CMS' Final Rule: Don't Neglect CMS NCCI Edits
- 4 Drivers of Recent M&A Activity in Healthcare
- 8 Reasons to Outsource Medical Billing Services
- 5 ICD-10 Transition Considerations Medical Practices Have Likely Not Thought About